# Cambridge Epigenetix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cambridge-epigenetix

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.cambridge-epigenetix.com
- Total disclosed funding: $150M
- Latest round: Series D (Nov 2, 2021)
- Investors on record: 9

## About

Cambridge Epigenetix Limited specializes in innovative DNA-sequencing technology, focusing on multiomic analysis to advance genetic and epigenetic research.Founded in 2012 and based in Cambridge, UK, Cambridge Epigenetix Limited offers advanced solutions for genomic studies. The company raised GBP 71.73 million in Series D funding on November 2, 2021, led by Temasek Holdings, with participation from several prominent investors. Bobby Yerramilli-Rao is the founder, contributing significant expertise in the field.Cambridge Epigenetix Limited primarily offers the duet multiomics solution evoC, designed for comprehensive analysis of genetic and epigenetic information from a minimal DNA sample. The technology identifies a 6-base genome, differentiating traditional DNA bases from key epigenetic modifications, such as 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC). Targeted at academic institutions, biotech firms, and healthcare providers, the products support research in cancer, neurodegenerative diseases, and precision medicine across North America, Europe, and parts of Asia.In 2023, Cambridge Epigenetix Limited reported revenue of GBP 745,298.80, with an EBITDA of -GBP 23,483,903.10. The revenue model is based on direct sales of the duet multiomics solution evoC to research institutions and pharmaceutical companies, with potential bulk purchasing agreements enhancing client engagement.The recent funding round of GBP 71.73 million will support the further advancement and commercialization of Cambridge Epigenetix Limited's DNA-sequencing technology platform. The company aims to expand its product offerings and penetrate new markets, leveraging its innovative solutions to address growing demands in genomic and epigenetic research.

## Funding rounds

- Series D, Nov 2, 2021, $98M — Hong Shan, Temasek Holdings, Third Point, GV, New Science Ventures, Ahren Innovation Capital
- Series C, Jan 10, 2019, $26M — Hong Shan, GV, New Science Ventures, DNA Capital, Ahren Innovation Capital
- Series B, Mar 14, 2016, $20M — Hong Shan, Cambridge Enterprise, GV, New Science Ventures, Syncona
- Series A, Aug 4, 2014, $5.7M — Cambridge Enterprise, New Science Ventures, Syncona

## Investors

- Cambridge Enterprise — Series A, Series B
- New Science Ventures (https://capitalatlas.ai/funds/new-science-ventures) — Series A, Series B, Series C, Series D
- Syncona (https://capitalatlas.ai/funds/syncona) — Series A, Series B
- Hong Shan — Series B, Series C, Series D
- GV (https://capitalatlas.ai/funds/gv) — Series B, Series C, Series D
- DNA Capital — Series C
- Ahren Innovation Capital (https://capitalatlas.ai/funds/ahren-innovation-capital) — Series C, Series D
- Temasek Holdings — Series D
- Third Point (https://capitalatlas.ai/funds/third-point) — Series D